-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II

Symposia: Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Alexandre Guy, MD, PhD1,2*, Olivier Mansier, PharmD, PhD1,3*, Alexandre Catherineau4*, Geoffrey Garcia, PharmD1*, Sylvie Labrouche-Colomer, PharmD, PhD1,3*, Valentin Landrieu, PharmD3*, Marie-Lise Bats, PharmD, PhD1,5*, Francoise Boyer, MD6*, Jean-Christophe Ianotto, MD, PhD7*, Lydia Roy, MD8*, Suzanne Tavitian, MD9*, Borhane Slama, MD10*, Stephane Girault, MD11*, Gabriel Etienne, MD, PhD12*, Anne Parry, MD13*, Arnaud Saint-Lezer, MD14*, Guillaume Denis, MD15*, Clemence Mediavilla, MD16*, Jean-Francois Viallard, MD PhD17*, Laurence Legros, MD, PhD18*, Dana Ranta, MD19*, Mathieu Wemeau, MD20*, Franck E. Nicolini, MD, PhD21, Francois Lifermann, MD22*, Nathalie Cambier, MD23*, Luc Darnige, MD24*, Francois Girodon, MD, PhD25*, Juliette Soret-Dulphy26*, Emilie Cayssials, MD, PhD27*, Fabienne Vacheret, MD28*, Léa Sureau29*, Damien Luque-Paz, PharmD, PhD30*, Valérie Ugo, MD, PhD29*, Jean-Jacques Kiladjian, MD, PhD31, Rodolphe Thiébaut, MD, PhD4* and Chloe James, MD, PhD1,3*

1Biology of Cardiovascular Diseases, University of Bordeaux, INSERM, UMR1034, Pessac, France
2Bordeaux University Hospital, PESSAC, France
3Laboratory of Hematology, Bordeaux University Hospital, Pessac, France
4Department of Medical Information, Bordeaux University Hospital, Bordeaux, France
5Laboratory of Biochemistry, Bordeaux University Hospital, Bordeaux, France
6Department of Hematology, Angers University Hospital, Angers, France
7Department of Hematology, Brest University Hospital, Brest, France
8Hematology Department, Henri Mondor University Hospital, UPEC, IMRB, Assistance Publique Hopitaux de Paris, Créteil, France
9Department of Hematology, Toulouse University Cancer Institute Oncopole, Toulouse University Hospital, Toulouse, France
10Department of Hematology, Avignon Hospital Center, Avignon, France
11Department of Hematology, Limoges University Hospital, Limoges, France
12Hematology, Institut Bergonié, Bordeaux, France
13Department of Hematology, Annecy Genevois Hospital Center, Pringy, France
14Department of Hematology, Mont-De-Marsan Hospital Center, Mont-De-Marsan, France
15Department of Hematology, Rochefort Hospital, Rochefort, France
16Hematology Department, CHU de Bordeaux, Bordeaux, France
17Department of Internal Medicine, Bordeaux University Hospital, Pessac, France
18Service d’Hématologie-Clinique Ambulatoire (SHCA), APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
19Department of Hematology, Nancy University Hospital, Vandoeuvre Les Nancy, France
20Department of Hematology, Roubaix Hospital, Roubaix, France
21Hematology Department, Centre Leon Berard, LYON Cedex 03, France
22Department of Internal Medicine, Dax Hospital, Dax, France
23Hematology department, Hospital of Valenciennes, Valenciennes, FRA
24Laboratory of Hematology, APHP Georges-Pompidou European Hospital, Paris, France
25Laboratory of Biological Hematology, University Hospital of Dijon, Dijon, France
26Clinical Investigation Center, Saint-Louis Hospital, Paris, France
27Hematology department & CIC, CHU Poitiers & INSERM CIC 1402, Poitiers, France
28Department of Hematology, Perpignan Hospital Center, Perpignan, FRA
29Laboratory of Hematology, Angers University Hospital, Angers, France
30Université Angers, Nantes Université, CHU Angers, INSERM, CNRS, CRI2NA, Angers, France
31Clinical Investigation Center, Hôpital Saint-Louis, Université de Paris, Paris, France

Lucas Wadley, BS1*, Hew Yeng Lai, PhD2*, Eshika Arora1*, Helen Huang3*, Jianhong C Heidmann, BS4*, Dennis Jing, BS5*, Lauren Chen1* and Angela G. Fleischman, MD, PhD4

1University of California, Irvine, Irvine, CA
2UCI, Irvine, CA
3Division of Hematology/Oncology, University of California, Irvine, IRVINE, CA
4Division of Hematology/Oncology, University of California, Irvine, Irvine, CA
5University of California, Irvine, Irvine

Yuka Sato1*, Koki Ueda, MD, PhD1, Keiji Minakawa, MS1*, Saori Miura, PhD1,2* and Kazuhiko Ikeda, MD, PhD1

1Department of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, Fukushima, Japan
2Department of Clinical Laboratory Sciences, School of Health Science, Fukushima Medical University, Fukushima, Japan

Abdulraheem Yacoub, MD1*, Ellen K. Ritchie, MD2, Naveen Pemmaraju, MD3, Richard Zuniga4*, Erin L. Crowgey, PhD5*, Cynthia Timmers, PhD5*, Patricia Feldman5*, J.E. Hamer-Maansson, MSPH5*, Tricia Kalafut5*, Evan M. Braunstein, MD, PhD5* and John O. Mascarenhas, MD6

1University of Kansas Medical Center, Westwood, KS
2Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
3The University of Texas MD Anderson Cancer Center, Houston, TX
4New York Cancer & Blood Specialists, New York, NY
5Incyte Corporation, Wilmington, DE
6Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Matteo Brindisi1,2*, Laura Crisafulli, PhD1,2*, Matteo Zampini, PhD1*, Mirko Liturri, MSc1*, Elena Riva, PhD1*, Elena Saba, PhD1*, Alessia Campagna, MD1*, Luca Lanino, MD1,3, Marta Ubezio, MD1*, Gabriele Todisco, MD3*, Giulia Maggioni, MD1*, Antonio Russo, MD1*, Nicla Manes, MSc1*, Denise Ventura, MSc1*, Nicole Pinocchio, MSc1*, Dario Strina1,2*, Lucia Susani1,2*, Matteo Giovanni Della Porta, MD1,3* and Francesca Ficara, PhD1,2*

1IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy
2Institute for Genetic and Biomedical Research, Milan Unit, CNR, Milan, Italy
3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

Chen Jia1*, Ting Sun1*, Renchi Yang1*, Rongfeng Fu, MD1* and Lei Zhang1,2

1Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China, Tianjin, China

Hosuk Ryou1*, Laura Harding2*, Jens Rittscher1* and Daniel Royston, DPhil, FRCPath, MBBChir3

1Institute of Biomedical Engineering, University of Oxford, Oxford, United Kingdom
2Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
3Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, United Kingdom

Saori Miura, PhD1,2*, Koki Ueda, MD, PhD2, Tomofumi Misaka, MD, PhD3*, Masato Matsuda, PhD1*, Keiji Minakawa, MS2*, Yuka Sato2*, Yasuchika Takeishi, MD, PhD3* and Kazuhiko Ikeda, MD, PhD2

1Department of Clinical Laboratory Sciences, School of Health Science, Fukushima Medical University, Fukushima, Japan
2Department of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, Fukushima, Japan
3Department of Cardiovascular Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan

Xiaoshuai Zhang1*, Zongru Li, MD2*, Lu Yu3*, Mei Bao4* and Qian Jiang, MD2,5,6

1Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China
2Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
3National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
4Peking University People's Hospital, Beijing, China
5National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, Beijing, China
6Peking University People’s Hospital,Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China

Warren C. Fiskus, BSc, PhD1, Lucia Masarova, MD2, Christopher Peter Mill, PhD, BA3, Christine Birdwell, PhD3, Kaberi Das, PhD1*, John A. Davis3*, Hanxi Hou4*, Kevin Philip4*, Alicia Matthews4*, Taghi Manshouri, PhD2*, Surbhi Sharma, PhD5, Tapan M. Kadia, MD2, Courtney D. DiNardo, MD, MSc6, Prithviraj Bose, MD4, Naveen Pemmaraju, MD7, Sanam Loghavi, MD8, Marie Törngren, PhD9* and Kapil N. Bhalla, MD1

1UT MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3MD Anderson Cancer Center, Houston, TX
4The University of Texas MD Anderson Cancer Center, Houston, TX
5The UT MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
9Active Biotech, Lund, Sweden

Hanqian L Carlson1*, Samantha Tauchmann, PhD2*, Thai Nguyen, MS1*, Sarah A Carratt, PhD, DABT3*, Tao Liu4*, Theodore P Braun, MD, PhD1,5,6,7 and Julia E Maxson, PhD1,5,7

1Oregon Health & Science University, Portland, OR
2Oregon Health and Scienc University, Portland,, OR
3Oregon Health and Science University, Portland, OR
4Biological Sciences Division, Pacific Northwest National Laboratories, Richland,, WA
5Knight Cancer Institute, Oregon Health & Science University, Portland, OR
6Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
7Division of Oncologic Sciences, Oregon Health & Science University, Portland, OR

Graeme Greenfield, BA, MRCP, BMBS1*, Yu Sheng1*, Lisa J Crawford, BSc, PhD2*, Yaser Atlasi, PhD1*, Dan Longley, PhD1*, Ken I Mills, PhD, FRCPath2 and Mary Frances McMullin, MD, FRCPath, FRCP3

1Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom
2Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, NI, United Kingdom
3BHSCT, Belfast, United Kingdom

Stephen T. Oh, MD, PhD1*, Jeffrey I. Zwicker, MD2,3, Kamal Patel, MD4*, Erin L. Crowgey, PhD5*, Cynthia Timmers, PhD5*, Patricia Feldman5*, Justine Carl5*, J.E. Hamer-Maansson, MSPH5*, Valkal Bhatt, PharmD5*, Evan M. Braunstein, MD, PhD5* and Michael R. Grunwald, MD6

1Washington University School of Medicine, St. Louis, MO
2Weill Cornell Medical College, New York, NY
3Memorial Sloan Kettering Cancer Center, New York, NY
4CARTI Cancer Center, Little Rock, AR
5Incyte Corporation, Wilmington, DE
6Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

Charlotte K Brierley, bmbch1, Charlotte Gaskell, BSc MSc2*, Claire Harrison3, Christina Yap, PhD2,4*, Aimee Jackson, BSc MSc2*, Jennifer Byrne, FRCP FRCPath PhD5*, Angela Hamblin, MD, PhD6*, Sally-Ann Clark, PhD, BSc1*, Jennifer O Sullivan, MD PhD1,7*, Alba Rodriguez-Meira, PhD1,8,9*, Lauren Murphy, BSc1*, Fiona Jane Clarke, MD10*, Srinivasan Narayanan, FRCP, FRCPath11*, David T. Bowen, MD, PhD12*, Emma Gudgin, MBBS, MRCP, FRCPath, PhD13*, Dragana Milojkovic, MBBS, MRCP, FRCPath, PhD14*, Rebecca Collings2*, Bethan Psaila, MD, PhD15, Steve Knapper, MRCP, FRCPath, DM16*, Mark W. Drummond, PhD, FRCPath17* and Adam J Mead, PhD, MRCP, FRCPath18

1Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM) and NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
2Cancer Research UK Trials Unit, University of Birmingham, Birmingham, United Kingdom
3Guy's and St Thomas' NHS Foundation Trust, London, ENG, United Kingdom
4The Institute of Cancer Research, Sutton, ENG, GBR
5Nottingham University Hospitals NHS Trust, Nottingham, GBR
6Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
7Dept of Haematology, Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom
8Broad Institute of MIT and Harvard, Cambridge, MA
9Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA
10University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
11University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
12St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, GBR
13Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
14Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, GBR
15Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, Oxford, ENG, United Kingdom
16School of Medicine, Cardiff University, Cardiff, United Kingdom
17Dept of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
18Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), University of Oxford, Oxford, United Kingdom

Florian Siegerist1,2*, Tina M Schnoeder, PhD3*, Ashok Kumar Jayavelu, PhD.4,5*, Florian Perner, MD6, Philipp Jost7*, Elke Hammer8*, Uwe Völker8*, Karen Lopez-Cayuqueo9*, Kai Schmidt-Ott9*, Maike Büttner-Herold, MD10*, Nicole Endlich2,11* and Florian H. Heidel, MD12,13

1Department of Pediatrics, University Medicine Greifswald, Greifswald, Germany
2Institute of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany
3Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany
4German Cancer Research Center (DKFZ), Heidelberg, Germany
5Max-Planck-Institute of Biochemistry, Munich, Germany
6Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
7Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria
8Institute of Functional Genomics, University Medicine Greifswald, Greifswald, Germany
9Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
10Department of Nephropathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
11NIPOKA GmbH, Greifswald, Germany
12Leibniz Institute on Aging, Fritz-Lipmann-Institute, Jena, Germany
13Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

John O. Mascarenhas, MD1, Uma Borate, MD2, Prithviraj Bose, MD3, John C. Byrd, MD4, Jacqueline S. Garcia, MD5, Michael R. Grunwald, MD6, Gabriela S. Hobbs, MD7, Ronald Hoffman, MD8, Andrew T. Kuykendall, MD9, Ruben A. Mesa, MD10, Stephen Oh, MD, PhD11, Raajit Rampal, MD, PhD12, Abdulraheem Yacoub, MD13 and David P. Steensma, MD14

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2The Ohio State University, Columbus, OH
3The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
6Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
7Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA
8The Tisch Cancer Institute, Division of Hematology & Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
9Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
10Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC
11Washington University School of Medicine, Saint Louis, MO
12Memorial Sloan Kettering Cancer Center, New York, NY
13University of Kansas Cancer Center, Leawood, KS
14Ajax Therapeutics, Cambridge, MA

*signifies non-member of ASH